Table III.
Factors associated with occurrence of physician-diagnosed recurrent wheezing by multiple logistic regression for subgroups based on family history
| Odds ratio (95% CI) |
||||
|---|---|---|---|---|
| No history |
History |
|||
| Variable | vs combined untreated groups | vs untreated non-RSV hospitalized group | vs combined untreated groups | vs untreated non-RSV hospitalized group |
| Asthma | ||||
| Palivizumab treatment | 0.32 (0.14-0.75)† | 0.32 (0.13-0.80)∗ | NA | NA |
| Member of multiple birth | NA | NA | 6.63 (1.64-26.74)† | NA |
| Siblings in household | NA | NA | 0.30 (0.09-0.98)∗ | NA |
| Siblings in day care | NA | NA | 5.40 (1.47-19.86)∗ | 2.02 (1.07-3.82)∗ |
| Birth weight | 0.35 (0.15-0.81)∗ | NA | NA | NA |
| Gestational age (per 1-wk increase) | NA | 0.78 (0.66-0.93)† | NA | NA |
| Atopy (asthma, atopic dermatitis, or allergic rhinitis) or food allergies | ||||
| Palivizumab treatment | 0.20 (0.07-0.59)† | 0.18 (0.06-0.55)† | NA | NA |
| Family history of asthma | NA | NA | NA | 3.10 (1.12-8.62)∗ |
| Gestational age (per 1-wk increase) | 0.82 (0.68-0.98)∗ | 0.79 (0.65-0.96)∗ | NA | 0.80 (0.64-1.00)∗ |
NA, not applicable, variable was not included in the final model.
∗
Statistically significant at the .050 level.
†
Statistically significant at the .010 level.